Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Université Paris-Saclay · Institut Gustave Roussy · +32 more institutions
Abstract
alteration. Data are needed to confirm and expand on the findings of the phase 2 study.
alteration and who had disease progression after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI). We randomly assigned the patients in a 2:1 ratio to receive oral rucaparib (600 mg twice daily) or a physician's choice control (docetaxel or a second-generation ARPI [abiraterone acetate or enzalutamide]). The primary outcome was the median duration of imaging-based progression-free survival according to independent review.
Citation impact
- FWCI
- 98.64
- Percentile
- 100%
- References
- 33
Authors
28- KFKarim FizaziCorresponding
Université Paris-Saclay, Institut Gustave Roussy, Research Institute in Oncology and Hematology
- JMJosep M. Piulats
Université Paris-Saclay, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Research Institute in Oncology and Hematology
- MNM. Neil Reaume
Université Paris-Saclay, Ottawa Hospital, Research Institute in Oncology and Hematology, Ottawa Hospital Research Institute
- POPeter Ostler
Université Paris-Saclay, Mount Vernon Cancer Centre, Research Institute in Oncology and Hematology
- RMRay McDermott
Université Paris-Saclay, Cancer Trials Ireland, St. Vincent's University Hospital, Research Institute in Oncology and Hematology
Topics & keywords
- Prostate cancer
- Medicine
- Oncology
- Cancer
- Prostate
- Internal medicine
- Good health and well-being